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ABSTRACT:
SNF2L, an ATPase chromatin remodeling gene nearly ubiquitously expressed in diverse 
tissues, cancers, and derived cell lines, contributes to the chromatin remodeling 
complex that facilitates transcription. Because of this near ubiquitous expression, it has 
not been exploited as a cancer therapeutic target. However, in a recent study, we found 
that highly malignant cancer cells, although expressing SNF2L at similar levels as their 
normal counterparts, were sensitive to its knockdown. Only the highly malignant (HM) 
lines showed significant growth inhibition, DNA damage, a DNA damage response, and 
phosphorylation of checkpoint proteins and marked apoptosis. In studying SNF2L, we 
discovered a novel truncated isoform, SNF2LT which, when compared to full length 
SNF2L, lacked three important domains: HAND, SANT and SLIDE. Although truncated 
isoforms usually have antagonistic functions to their parental molecule, here SNF2LT 
knockdown had similar effects to the knockdown of its parental molecule, SNF2L, 
of inducing DNA damage, a DNA damage response, cell cycle arrest and apoptosis 
selectively in cancer cell lines. However dual SNF2L and SNF2LT knockdown, while 
inducing DNA damage, did not result in a DNA damage response, a cell cycle arrest 
and apoptosis. In fact HM lines subjected to dual knockdown paradoxically exhibited 
sustained cell growth. Our findings indicate that the ratio of SNF2L to its isoform 
tightly regulates the cancer cell’s response to DNA damage. Cancer cell lines which 
endogenously express low levels of both SNF2L and its isoform mimic the situation of 
dual knockdown and permit DNA damage which is allowed to propagate unchecked.
INTRODUCTION
Aberrant gene function and altered patterns of gene 
expression are key features of cancer. An explosion of 
data indicating the importance of epigenetic processes, 
especially those resulting in the silencing of key regulatory 
genes, has led to the realization that genetics and 
epigenetics cooperate at all stages of cancer development 
[1-5].  Epigenetic  modifications  fall  into  two  main 
categories: DNA methylation and histone modifications 
[6-10]. The processes of covalent histone modification 
and DNA methylation couple with chromatin remodeling 
by ATP-dependent remodeling machines to obtain 
efficient transcriptional regulation, DNA replication and 
DNA-damage repair [11-15]. Emerging data have shown 
that ATPase-dependent remodeling enzymes all act in 
the context of multisubunit complexes, which adds an 
additional layer of fine-tuned specificity in ATP-dependent 
chromatin remodeling [16-20]. 
SNF2L (SMARCA1), an ATPase chromatin 
remodeling gene nearly ubiquitously expressed in diverse 
tissues, cancers, and derived cell lines, contributes Oncotarget 2012; 3:  475-489 476 www.impactjournals.com/oncotarget
Figure 1: Comparisons of SNF2L (SMARCA1) with SNF2LT (A1IS). A, the exon/intron map of SNF2L/SNF2LT is depicted. 
B, the RT-PCR strategy to amplify both SNF2L and SNF2LT is depicted. C, the structural/functional domains of SNF2L are compared to 
those of SNF2LT. D, detailed comparisons of intron and exon sequences present in SNF2L (SMARCA1) and SNF2LT (A1IS). Two variants 
of parental SNF2L (SNF2L-a and SNF2L-b) are depicted. Each experiment was performed in triplicate and repeated at least four times.Oncotarget 2012; 3:  475-489 477 www.impactjournals.com/oncotarget
to the chromatin remodeling complex that facilitates 
transcription. Because of this near ubiquitous expression, 
it has not been exploited as a cancer therapeutic target. 
However, in a recent study [21], we found that cancer 
cells, although expressing SNF2L at similar levels as 
their normal counterparts, were exquisitely sensitive to 
its knockdown. This was not observed when its imitation 
SWI  ortholog,  SNF2H,  was  inhibited.  SNF2L  siRNA 
inhibition using two different siRNAs separately reduced 
SNF2L transcript levels and protein in both normal and 
cancer  lines,  but  only  the  cancer  lines  showed  DNA 
damage, a DNA damage response, phosphorylation of cell 
cycle checkpoint proteins, significant growth inhibition 
and marked apoptosis. 
SNF2L, the ISWI family member of the SNF2 
ATPase superfamily in humans, is one subunit of the ATP-
dependent chromatin complex hNURF. The other two 
subunits of hNURF are BPTF and RbAP46/RbAP48 [22]. 
The data have shown that NURF regulates expression of 
homeotic genes, modulates Wnt-signaling, and affects 
higher-order chromatin structure; in vitro NURF catalyzes 
formation of regularly spaced nucleosomal arrays and 
facilitates transcription activation [23,24]. 
The SNF2L gene encodes a 1054-amino acid protein 
with six putative conserved domains: SNF2_L, DEXHc, 
HELICc, HAND, SANT and SLIDE [25]. The SNF2_N 
(SNF2 family N-terminal domain) (186-466 aa) is found 
in proteins involved in a variety of processes including 
transcription regulation, DNA repair, DNA recombination, 
and  chromatin  unwinding.  DEXHc  contains  the ATP-
binding region and is found in a diverse family of proteins 
involved in ATP-dependent DNA or RNA unwinding. 
HELICc (Helicase superfamily c-terminal domain) (477-
620 aa) is found in a wide variety of helicases and helicase 
related proteins; it utilizes the free energy from nucleoside 
triphosphate hydrolysis to fuel their translocation along 
DNA, unwinding the duplex in the process. HAND (the 
HAND domain) (758-838 aa) adopts a secondary structure 
consisting of four alpha helices, three of which (H2, H3, 
H4) form an L-like configuration. The domain confers 
DNA and nucleosome binding properties to the protein. 
Tandem copies of the SANT (‘SW13, ADA2, N-CoR and 
TFIIIB’ DNA-binding domains) domain bind telomeric 
DNA tandem repeats as part of the capping complex. 
Binding is sequence dependent for repeats which contain 
the G/C rich motif [C2-3A(CA)1-6]. The domain is also 
found in regulatory transcriptional repressor complexes 
where it also binds DNA. The SLIDE domain (913-1022 
aa) adopts a secondary structure comprising a main core 
of three alpha-helices. It has a role in DNA binding, 
contacting DNA target sites similar to c-Myb repeats or 
homeodomains. SANT and SLIDE domains also mediate 
interaction with unmodified histone tails and linker DNA.
In studying SNF2L, we discovered a novel truncated 
Figure 2: SNF2L and SNF2LT expression by RT-PCR in different normal human tissues, cancers and cell lines. A, 
expression of SNF2L and SNF2LT by RT-PCR in different human normal tissues. SNF2L was nearly ubiquitously expressed in human 
normal tissues with especially high expression in ovary and testis; SNF2LT was similarly expressed though only at a molar fraction of the 
level of SNF2L. B, both SNF2L as well as SNF2LT were expressed in all tested human cancer tissues. C, both SNF2L and SNF2LT were also 
expressed in nearly all human cancer cell lines with the exception of MARY-XT (xenograft tumor) and in vitro derived spheroids (MARY-X 
SP), both derived from a patient with inflammatory breast cancer (26,27). ACTB served as housekeeping control. Each experiment was 
performed in triplicate and repeated at least four times.Oncotarget 2012; 3:  475-489 478 www.impactjournals.com/oncotarget
isoform, SNF2LT, which, when compared to full length 
SNF2L lacked three important domains: HAND, SANT 
and  SLIDE.  Because  SNF2L  knockdown  had  such  a 
selective effect on highly malignant (HM) lines [21) and 
the presence of an altered functional splice variant might 
suggest an additional level of biological complexity in the 
regulation of the action of SNF2L, we decided to study 
both molecules and their relationship in detail in the 
present study. 
MATERIALS AND METHODS
Reagents and antibodies
All antibodies used were rabbit polyclonal unless 
otherwise indicated and included an antibody to SNF2L 
(SMARCA1; ab37003; Abcam, Inc.). Antibodies used for 
detection of DNA damage were obtained from the DNA 
Damage Antibody Sampler (Cell Signaling Technology, 
Inc.,  Danvers,  MA),  which  included  Phospho-ATR 
(Ser428), Phospho-ATM (Ser1981) mouse monoclonal 
antibody (mAb), Phospho-BRCA1 (Ser1524), Phospho-
CHK1  (Ser296),  Phospho-CHK2  (Thr68),  Phospho-
Histone H2AX (Ser139), and Phospho-p53 (Ser15; 16G8) 
mouse mAb. p53 (7F5) rabbit mAb and β-actin (13E5) 
rabbit mAb were also used (Cell Signaling Technology, 
Inc.). Antibodies for detection of cell cycle checkpoints 
used the Cell Cycle/Checkpoint Sampler kit (Cell 
Signaling Technology, Inc.), which included Phospho-cdc2 
(Tyr15) and Phospho-Rb (Ser795). Additional antibodies 
that recognized total protein levels of the respective 
DNA damage proteins (CHK1, CHK2, BRCA1, ATR, 
and H2AX) and cell cycle checkpoint proteins (cdc2, 
Rb,  mouse  mAb)  were  also  obtained  (Cell  Signaling 
Technology, Inc.). Secondary antibodies and Western 
blotting substrates were obtained (Pierce Biotechnology, 
Inc., Rockford, Il). Human tumor total RNAs and the 
FirstChoice Human Total RNA Survey Panel were also 
used (Ambion, Inc., Austin, TX). 
Cell lines and human tissues
All  the  cell  lines  were  grown  under  standard 
conditions in DMEM with 10% fetal bovine serum with 
Figure 3: Singular v dual knockdown of SNF2L and SNF2LT and cell growth. A, siRNAs and their targeted areas are depicted. 
B, SNF2L siRNA (12578) selectively knocked down SNF2L; SNF2LT siRNA (A1IS) selectively knocked down SNF2LT; and SNF2L/T 
siRNA (12667) knocked down both SNF2L as well as its isoform, SNF2LT. siRNA (NCSI) (RNAi-neg) was used as the negative control. 
ACTB served as housekeeping gene. C, singular knockdown of either SNF2L or SNF2LT significantly inhibited the growth of HM lines 
(MDA-MB-468 and MDA-MB-231). Dual knockdown of SNF2L as well as SNF2LT, however, was permissive of growth in HM lines. 
Each experiment was performed in triplicate and repeated at least four times.Oncotarget 2012; 3:  475-489 479 www.impactjournals.com/oncotarget
the exception of the fibroblast lines, which were grown 
in MEM-α medium with 10% fetal bovine serum, and 
the  myoepithelial  lines,  which  were  grown  in  KSFM 
with  supplements  (Life  Technologies,  Inc.,  Grand 
Island, NY). All lines, unless otherwise indicated, were 
obtained from a single source (American Type Culture 
Collection, Manassas, VA) and were human and consisted 
of the following: HM: estrogen receptor–negative breast 
cancer lines (MDA-MB-231, MDA-MB-468), Her-2/
neu–amplified  breast  cancer  lines  (HCC202,  HTB20; 
HTB27),  an  inflammatory  breast  cancer  xenograft, 
MARY-X, established by us [26,27], a cervical squamous 
cell carcinoma (HeLa), a rhabdomyosarcoma (RB), a 
leiomyosarcoma (SKLMS-1), and an osteosarcoma (U2-
0S) line; NU: three fibroblast lines including dermal HDF 
and pulmonary HLF, (gifts of Dr. Issekutz, Dalhousie 
University, Halifax, Canada) and skin OSU-2 (a gift of 
Altaf Wani, Ohio State University, Columbus, OH), a 
mammary epithelial line (HMEC; Clonetics), and the 
nontumorigenic  estrogen  receptor–negative  MCF-10A 
line; and benign or LG lines and xenografts: HMS-X and 
HMS-1, derived by us from a benign human myoepithelial 
salivary gland tumor and HMS-3X, HMS-4X, and HMS-
6X, derived from other benign matrix-secreting human 
myoepithelial tumors from salivary gland, breast and 
pulmonary  sources  [28],  and  the  estrogen  receptor–
positive  breast  carcinoma  MCF-7. All  the  lines  were 
grown under standard conditions. 
Human tissues (normal and tumoral) were obtained 
from the frozen tissue bank of the Human Tissue Network 
at the Ohio State University.
siRNA transfections
The Silencer Pre-designed siRNA against human 
SNF2L (ID#12578) was obtained (Ambion, Inc.). The 
target site of siRNA was Exon 2 of SNF2L. The sequences 
of  siRNA  oligonucleotide  duplex  were  as  follows: 
5’-GGAAAUGGACCCAGAAUAUTT-3’ (sense) and 
5’-AUAUUCUGGGUCCAUUUCCTT-3’ (antisense). 
The siRNA oligonucleotide duplex targeted to SNF2LT 
(A1IS) was synthesized (Integrated DNA Technologies, 
Inc., Coralville, IA) and their sequences were as follows: 
5’-CAUGAUCUAUGGGUCAGAUUU-3’ (sense) and 
5’-AUCUGACCCAUAG AUCAUGUU-3’ (antisense). 
The target site of siRNA (ID#12667) was exon 18 of 
SNF2LT but exon 19 of SNF2L. Negative control siRNA 
(ID#AM4611)  (NCSI)  was  obtained  (Ambion,  Inc.). 
Cells  were  reverse  transfected  with  siRNA  (50  nM) 
using Lipofectamine RNAiMAX Transfection Reagent 
(Invitrogen Corporation, Inc.).
Plasmid constructions
Human  full-length  SNF2L  ORF  cDNA  was 
synthesized by RT-PCR using the human breast carcinoma 
cell line MDA-MB-468 cDNA as template. SNF2L cDNA 
and SNF2LT were separately cloned into vector pCR2.1-
TOPO (Invitrogen, Inc., Carlsbad, CA) and sequenced. 
The  SNF2LT  ORF  was  subcloned  into  pcDNA™6.2/
Myc-His-A to construct the SNF2LT expression vector 
pcDNA™6.2/SNF2LT-Myc-His  with  the  C-terminal 
myc epitopes and the polyhistidine tags. This vector was 
transfected directly into cultured cells using Lipofectamine 
2000 (Invitrogen, Inc.). (See Supplementary Information 
on line).
Cell growth, cell cycle and apoptosis experiments
Cells were transfected with the different siRNAs 
and seeded in 24-well cell culture plates. The number 
of viable cells in each well was counted every 24 h for 
3 d using trypan blue exclusion. The cell growth study 
was carried out in triplicate and repeated at least four 
times. For cell cycle analysis, the cells were collected 
12 to 24 h after transfection and fixed in 70% ethanol at 
−20°C, followed by washing once in PBS and staining in 
PI solution (69 mmol/L PI, 388 nmol/L sodium citrate, 
Figure 4: Singular v dual knockdown of SNF2L and 
SNF2LT and DNA damage. A, MDA-MB-468 cells were 
transfected with SNF2L siRNA, SNF2L siRNA or NCSI. 48 
hours  after  transfection,  DNA  damage  was  analyzed  by  the 
Comet assay and the results showed damaged DNA (the comet 
tail) outside the nucleus after treatment of SNF2LT siRNA 
(lower  panel),  SNF2L  siRNA  (middle  panel)  compared  to 
undamaged DNA in the cells treated with NCSI (upper panel). 
B, the surrogate DNA damage gene, p-H2AX showed increased 
expression  following  either  SNF2L  or  SNF2LT  knockdown 
(upper panel) and increased fold expression of p-H2AX (lower 
panel). Each experiment was performed in triplicate and repeated 
at least four times.Oncotarget 2012; 3:  475-489 480 www.impactjournals.com/oncotarget
100 μg/mL RNase A) for 15 min at room temperature. 
Ten thousand cells were analyzed on Coulter Epics XL 
flow cytometer (Beckman Coulter, Inc., Brea, CA). For 
the apoptosis assay, cells were harvested at 48 to 72 h 
following transfection. The apoptosis assay used Annexin 
V-FITC and PI (kit PN IM2375, Beckman Coulter, Inc.) 
with flow cytometric analysis.
DNA damage and the DNA damage response with 
apoptosis inhibition
To  determine  the  order  of  cellular  events  with 
SNF2L, SNF2LT or dual knockdown, selected cell lines, 
e.g., MDA-MB-468 cells, were seeded in six-well plates 
and incubated in 37°C overnight. Cells were treated first 
with general caspase inhibitors (Caspase Inhibitor Set 
IV, EMD Chemicals, Billerica, MA) for 45 min and then 
with the different siRNA’s for 24 h. Treated cells were 
collected and divided into three aliquots: the first aliquot 
was analyzed for apoptosis; the second aliquot was studied 
for DNA damage by the CometAssay; and a third aliquot 
was analyzed for protein levels of p-H2XA. 
Alkaline comet assay
The CometAssay (single-cell gel electrophoresis 
assay; Trevigen, Inc., Gaithersburg, MD) was used to 
evaluate DNA damage. The technique used electrophoresis 
of lysed cells embedded in an agarose gel, diluted in a 
SYBR green solution and viewed by DNA fluorescence. 
Cells with damaged DNA exhibited migration of their 
DNA outside of the nucleus, producing a comet tail. 
RNA isolation and cDNA synthesis
The total RNA was isolated from cultured cells using 
RNeasy Mini Kit (Qiagen Inc., Valencia, CA). Total RNA 
was dissolved in RNase-free water and the concentration 
determined by measuring absorbance using Nanodrop 
spectrophotometer  at  260  nm.  For  first  strand  cDNA 
synthesis, SuperScript® III First-Strand Synthesis System 
(Invitrogen, Inc.), ologo (dT)20 and 1 μg of total RNA 
were used. The synthesized cDNA was used for regular 
RT-PCR or real-time PCR analysis of relative expression 
levels of target genes.
Figure 5: Singular v dual knockdown of SNF2L and SNF2LT and the cell cycle. MDA-MB-468 cells were transfected 
with the different siRNAs. A, singular knockdowns of either SNF2L or SNF2LT both led to substantial increases in p53 mRNA but dual 
knockdowns affected p53 mRNA less so by real time RT-PCR. B, singular knockdowns of either SNF2L or SNF2LT both led to substantial 
increases in the p53 target gene, 14-3-3σ but dual knockdowns did not affect 14-3-3σ. C, singular knockdowns of either SNF2L or SNF2LT 
both led to substantial increases in another p53 target gene, GADD45A but dual knockdowns did not affect GADD45A. Each experiment 
was performed in triplicate and repeated at least four times.Oncotarget 2012; 3:  475-489 481 www.impactjournals.com/oncotarget
RT and real-time PCR
An aliquot of 20 ng cDNA was used in each 25 μL 
PCR reaction, using Platinum Taq DNA Polymerase High 
fidelity (Invitrogen, Inc.). The following conditions used 
were as follows: denaturation at 94°C for 30 s, annealing 
at 58°C for 30 s, and extension at 68°C for 1 min for a 
total of 25, 30, or 35 cycles. PCR products were analyzed 
by 2.0% agarose gel. Real-time PCR was done on a ABI 
7500 Real-time PCR System (Applied Biosystems, Inc., 
Foster City, CA). cDNA was combined with primer sets 
and  Power  SYBR  Green  PCR  Master  Mix  (Applied 
Biosystems, Inc.) was used. Gene expression levels were 
calculated  relative  to  the  housekeeping  gene  β-actin 
(ACTB) by using 7500 System SDS software (Applied 
Biosystems,  Inc.).  Primer  sets  (forward  and  reverse) 
used for either RT-PCR or real-time PCR included the 
following (forward, reverse):
Human SNF2L: 
5’-ACGGCCTCCAAAACAGCCAAATG-3’, 
5’-TGAGCCAGAGCTGGATTTGGGATA-3’
ATM: 
5’-TGGATCCAGCTATTTGGTTTGA-3’, 
5’-CCAAGTATGTAACCAACAATAGAAGAAGTAG-3’
ATR: 
5’-TGTCTGTACTCTTCACGGCATGTT-3’,
5’-AGAGGTCCACATGTCCGTGTT-3’
CHK1: 
5’-GGTGAATATAGTGCTGCTATGTTGACA-3’, 
5’-TTGGATAAACAGGGAAGTGAACAC-3’
CHK2: 
5’-AGTGAGAGGACTGGCTGGAGTT-3’, 
5’-CCCAAGGCTCCTCCTCACA-3’
TP53: 
5’-TCAACAAGATGTTTTGCCAACTG-3’, 
5’-ATGTGCTGTGACTGCTTGTAGATG-3’
14-3-3σ: 
5’-TGCTGCCTCTGATCGTAGGAATTG-3’, 
5’-TTCCCTCAATCTCGGTCTTGCACT-3’
GADD45A: 
5’-TCAGCGCACGATCACTGTC-3’, 
5’-CCAGCAGGCACAACACCAC-3’
APAF-1: 
5’-GCATCACCCTTTGTAATAAC-3’, 
5’-CCCAGCTAATTTTTGTAGTT-3’
BAD:
5’-TTAAACCTGGCTCGCGACTT- 3 ‘,
5’ -GTGCTGTCTCCTTTGGAGGG-3’;
BAX: 
5’-CCTTTTCTACTTTGCCAGCAAAC-3’, 
5’-GAGGCCGTCCCAACCAC-3’
BIK: 
5’-CTTGATGGAGACCCTCCTGTATG-3’, 
5’ -AGGGTCCAGGTCCTCTTCAGA-3’
BAK1: 
5’-GAACAGGAGGCTGAAGGGGT-3’, 
5’ -TCAGGCCATGCTGGTAGACG-3’
BID: 
5’-GGTCTTACAGCAGGCAGTATCC-3’, 
5’-TCAGAATCTCTGTGCCATGTG-3’
BCL2: 
5’-GGAACAATGCAGCAGCCGAG-3’, 
5’-GTAGAGTGGATGGTCAGTGT-3’
CASP1: 
5’AATACTGTCAAATTCTTCATTGCAGATAA-3’,
5’-AAGTCGGCAGAGATTTATCCAATAA-3’
CASP3: 
5’-AGAACTGGACTGTGGCATTGAG-3’, 
5’-GCTTGTCGGCATACTGTTTCAG-3’
CASP6: 
5’-ACCTCCCACACTGGGAACCACA-3’, 
5’-CACCTGTATGACCAATTCCATGTC-3’
CASP7:
5’-AGTGACAGGTATGGGCGTTCG-3’,
5’-GCATCTATCCCCCCTAAAGTGG-3’
CASP8:
5’-CCTGGGTGCGTCCACTTT-3’, 
5’-CAAGGTTCAAGTGACCAACTCAAG- 3’
CASP9:
5’-ATAACCTTTTAGGCTGGTGG-3’, 
5’-AGAGCAGAAAGAGGTGAGAGA-3’
CASP10: 
5’-CCCTTAAACATTGGACAGTG-3’, 
5’ -GTGTAAATGAGCCATCATCTTC-3’
ACTB: 
5’-GGCACCCAGCACAATGAAG-3’, 
5’-GCCGATCCACACGGAGTACT-3’
Preparation of protein lysates and western blot 
analysis
To prepare protein lysates from cultured cell lines 
for western blot analysis, cells were lysed using ice-cold 
RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 50 mM Oncotarget 2012; 3:  475-489 482 www.impactjournals.com/oncotarget
NaF, 1 mM Na4P2O7•10 H2O, 0.1% DOC, 1.0% NP-
40, 50 μl Na3VO4, and Halt Protease Inhibitor Cocktail) 
(Pierce Biotechnology, Inc, Rockford, IL)). After 15 min 
on ice with shaking, the lysates were centrifuged at 15000 
× g for 10 min at 4°C. Supernatants were stored at -80°C 
until use. For western blot analysis, protein concentrations 
were determined using the BCA Protein Assay (Pierce 
Biotechnology, Inc). Equal amounts of boiled protein were 
loaded onto a 4-12% Precast gradient gel (Invitrogen, 
Inc.) and transferred to nitrocellular membranes. The 
membranes were washed in TBST buffer. Membranes 
were then washed and incubated with secondary antibody 
for 1 hour at room temperature. Bound antibodies were 
detected by a chemiluminescent detection system (West 
Femto; Pierce Biotechnology, Inc.).
Other studies
Additional studies of constitutive and conditional 
gene expression of SNF2L and SNF2LT were carried 
out with transient and stable transfection methods. (See 
Supplementary Information on line).
Institutional approvals and human tissues
Use of human tissues was approved by The Ohio 
State  University  Cancer  Institutional  Review  Board 
under protocol 2006C0042. Specifically, select normal 
and cancerous tissues were obtained from an anonymized 
frozen tissue bank. All animal and in vitro studies were 
approved by The Ohio State University’s Animal Care 
and Use Committee (Institutional Animal Care and Use 
Committee), protocol 2007A0218, and by the Institutional 
Biosafety Committee, protocol 2007R0057. Additional 
animal  studies  were  approved  by  the  University  of 
Nevada, Reno’s Institutional Animal Care and Use 
Committee, protocols 00439 and 00440.
Statistical analysis
All  experiments  performed  were  subjected  to 
statistical analyses. Each experiment was performed in 
triplicate and repeated at least four times. Representative 
results were depicted. Declarations of differences imply 
differences of statistical significance. Significance was 
assessed by the Student’s t-test. 
RESULTS
Serendipitous discovery of human SNF2LT 
(A1lS), a novel truncated isoform of human 
SNF2L
In initially studying SNF2L expression, it was noted 
that  the  expression  levels  of  SNF2L  were  highest  in 
ovary and testis [21]. The exon-intron map of SNF2L is 
depicted (Figure 1A). RNA from ovary was subjected to 
RT-PCR with primers which annealed to exon 17 located 
at  2097-2120  nt  of  SNF2L  (primer A1EX17FW)  and 
exon 19 at 2367-2384 nt (primer A1EX19RE) (Figure 
1B). The amplified products were separated on a 1.5% 
agarose  gel  and  stained  with  ethidium  bromide  (data 
not shown). As expected, one amplification product of 
approximately 300 bp was observed as the SNF2L cDNA 
product.  Interestingly,  we  found  another  amplification 
product about 550 bp in length. This 550-bp product 
was excised from the gel and purified and sequenced. 
Nucleotide sequencing revealed that the 5’end and 
the 3’end of the 550-bp product were the sequences of 
SNF2L cDNA. However, the central 250 bp fragment of 
this product did not match the sequence of SNF2L cDNA. 
We performed a blast analysis using the 250 bp fragment 
sequence on the NCBI website and discovered that this 
250 bp fragment was the whole sequence of intron 18 of 
the SNF2L gene. This raised the possibility that we might 
have stumbled on a novel alternatively spliced isoform 
of  SNF2L.  To  further  confirm  the  new  alternatively 
spliced mRNA containing intron 18 of SNF2L, we used 
two  pairs  of  primers  for  RT-PCR  that  covered  intron 
18 (Figure 1B). The primer SNF2LFW (A1FW) which 
annealed to the 5’end of SNF2L cDNA and SNF2LTRE 
(A1ISRE) which annealed to the 3’end of intron 18 were 
used to amplify the sequence that covered the 5’end of 
SNF2L and a significant portion of intron 18. The primer 
SNF2LTFW(A1ISFW) which annealed to the 5’end of 
intron 18 and SNF2LRE(A1RE) which annealed to the 
3’end of SNF2L cDNA were used to amplify the sequence 
that  covered  the  3’end  of  SNF2L  and  a  significant 
portion of intron 18. The amplified products were again 
separated on a 1.5% agarose gel and stained with ethidium 
bromide. As expected, two amplification products were 
observed: one approximately 2500-bp from primers 
SNF2LFW(A1FW) and SNF2LTRE(A1ISRE) and one 
about 1800-bp from primers SNF2LTFW(A1ISFW) and 
SNF2LRE(A1RE) (data not shown). The products were 
again excised from the gel and purified and sequenced. The 
nucleotide sequence confirmed that the full-length cDNA 
was a novel alternatively spliced mRNA isoform (named 
as SNF2LT(A1IS)) that contained full length intron 18 
(Figure 1B). Blast analysis of SNF2LT(A1IS) revealed 
that this isoform had not been previously reported. As Oncotarget 2012; 3:  475-489 483 www.impactjournals.com/oncotarget
schematically shown (Figure 1B), SNF2LT mRNA is 4310 
nucleotides in length compared to 4102 nucleotides of 
SNF2L mRNA. Intron 18 of the SNF2L gene is not spliced 
out but exists in SNF2LT mRNA as an exon sequence. 
Because a stop codon is introduced in intron 18, SNF2LT 
encodes only a 776 amino acid protein that lacks the 262 
amino acid C-terminal of SNF2L (Figure 1C; Figure 1D). 
SNF2LT also lacks 12 amino acids that correspond to 
amino acids 543–554 of the full length SNF2L protein 
(Figure 1D). Compared to the full length SNF2L protein, 
SNF2LT lacks three important domains: HAND, SANT 
and SLIDE (Figure 1C). We reported SNF2LT to GenBank 
(bankit1082498 EU36009).
Nearly ubiquitous expression of SNF2LT in both 
normal and cancerous human tissues and their 
derived cell lines 
Our previous results showed that human SNF2L 
was expressed nearly ubiquitously in both normal and 
human cancerous tissues and their derived cell lines [21]. 
Human SNF2LT was also expressed nearly ubiquitously in 
diverse normal (Figure 2A) and human cancerous tissues 
(Figure 2B) and their derived cell lines (Figure 2C) which 
included  highly  malignant  (HM),  low  grade  (LG)  or 
benign and normal untransformed (NU) human cell lines. 
Compared to SNF2L mRNA, the level of SNF2LT mRNA 
was usually lower than the level of SNF2L, averaging 
about 50% -75% lower on a molar basis (Figure 2A; 
Figure 2B; Figure 2C). The expression of SNF2LT also 
paralleled the expression of SNF2L: when the expression 
of SNF2L was high, as it was in the majority of HM lines 
examined, the expression of SNF2LT was also high; when 
SNF2L expression was low, so was the expression of 
SNF2LT. Interestingly the expression of SNF2L as well 
as its SNF2L isoform were low to absent in MARY-X, 
a transplantable human xenograft derived from a case of 
inflammatory breast cancer [26]. In both MARY-X and its 
in vitro derived spheroids thought equivalent to in vivo 
lymphovascular emboli, the expression of both SNF2L as 
well as SNF2LT remained low to absent. Although SNF2L 
was detected in murine tissues in a prior study [21], using 
equivalent primers, murine SNF2LT could not be detected 
(data not shown). Therefore it appeared as if SNF2LT 
might be a human specific isoform.
Singular v dual knockdowns of SNF2L/SNF2LT 
Singular v dual SNF2L and SNF2LT knockdowns 
could be achieved with targeted siRNA oligonucleotide 
duplexes (Figure 3A): the Silencer Pre-designed siRNA 
Figure 6: Singular v dual knockdown of SNF2L and SNF2LT and apoptosis. MDA-MB-468 cells were transfected with the 
different siRNAs. A, MDA-MB-468 cells were monitored over the next 48-72 hours with Annexin V-FITC and propidium iodide (PI) 
staining. The percentage of total apoptotic cells (early and late apoptosis) is depicted. Singular knockdowns of either SNF2L or SNF2LT 
both led to substantial increases in both early as well as late apoptosis. Dual knockdowns did not result in apoptosis over levels induced by 
the NCSI negative control (data not shown). During this time period the relative mRNA levels of potential genes involved in the apoptotic 
process was surveyed. B, singular knockdown of SNF2L led to a significant increase in Apaf-1 and caspase 9 whereas singular knockdown 
of SNF2LT led to a significant increase in caspase 8, BAD and BIK. C, dual knockdowns compared to NCSI knockdown did not result in 
a significant increase in any caspase. Each experiment was performed in triplicate and repeated at least four times.Oncotarget 2012; 3:  475-489 484 www.impactjournals.com/oncotarget
against human SNF2L (ID#12578) targeted against Exon 
2 of SNF2L; the siRNA oligonucleotide duplex targeted 
to SNF2LT (A1IS); and the siRNA (ID#12667) against 
exon  18  of  SNF2LT  and  exon  19  of  SNF2L.  siRNA 
(NCSI) was used as a negative oligonucleotide duplex 
control. These specific oligonucleotide duplexes achieved 
specific singular knockdowns of either SNF2L (RNAi-
12578) or SNF2LT (RNAi-A1IS) or dual knockdowns of 
both molecules (RNAi-12667) (Figure 3B). These results 
could be achieved in the diverse HM, LG or NU human 
cell lines which were examined. The specific knockdowns 
that were achieved were only partially predictable. A1IS 
siRNA targeted to “intron 18” that exists as an exon in 
A1IS mRNA but as an intron in SNF2L mRNA predictably 
knocked down SNF2LT (A1IS) but not SNF2L. 12578 
siRNA targeted to the 5’ part of both SNF2L and A1IS 
mRNA and 12667 siRNA targeted to exon 18 of A1IS 
mRNA but exon 19 of SNF2L. Both 12578 and 12667 
siRNAs might well be expected to separately knockdown 
both SNF2L as well as SNF2LT. However, 12578 siRNA 
selectively inhibited expression of SNF2L and had 
little effect on the expression of A1IS (Figure 3B). The 
molecular reasons for this selective knockdown were not 
clear. 12667 siRNA predictably led to the knockdowns of 
both SNF2L and A1IS (Figure 3B) and could be exploited 
to achieve dual knockdowns. 
Singular v dual knockdowns of SNF2L/SNF2LT 
and opposite effects on cell growth
After demonstrating that specific singular and dual 
knockdowns  of  full  length  SNF2L  and  its  truncated 
isoform, SNF2LT could be achieved, we next examined 
the  effects  of  these  knockdowns  on  cell  growth  of  a 
number of different cell lines including HM, LG and 
NU lines (complete list of lines examined provided in 
Materials  and  Methods).  Our  results  showed  that  the 
growth of all the HM lines examined were dramatically 
inhibited when singular knockdowns of either SNF2L or 
SNF2LT were achieved (Figure 3C). In the HM lines, eg., 
MDA-MB-468 and MDA-MB-231, not only was there 
growth inhibition but the cell numbers were reduced by 
day 3 below starting numbers indicating that, in addition to 
the growth arrest, that induction of cell death or apoptosis 
had occurred. When one looks closely at the cell numbers, 
one finds that the growth of the cells subjected to SNF2LT 
knockdown was even more reduced than the growth of the 
same cells subjected to SNF2L knockdown (Figure 3C). 
In contrast, the LG and NU lines showed substantially 
less growth inhibition with no reduction in cell numbers. 
The growth rate of the HM lines were essentially the same 
when transfected with the negative control siRNA (Figure 
3C). Dual knockdowns of SNF2L and SNF2LT, however, 
exhibited an increase in cell growth, findings dramatically 
opposite to the effects of singular knockdown (Figure 3C). 
Singular v dual knockdowns of SNF2L/SNF2LT 
and similar effects on DNA damage
In  a  recent  study  [21],  we  found  that  HM  cell 
lines, although expressing SNF2L at similar levels as 
their  normal  counterparts,  were  exquisitely  sensitive 
to  its  knockdown.  Only  HM  lines  showed  significant 
growth  inhibition,  DNA  damage,  a  DNA  damage 
response, and phosphorylation of checkpoint proteins 
and marked apoptosis. In that study we believed that 
SNF2L knockdown triggered DNA damage which then 
resulted in a DNA damage response which caused a cell 
cycle growth arrest and the induction of apoptosis. In 
the present study, we wanted to compare the effects of 
singular knockdown of SNF2LT with singular knockdown 
of SNF2L on DNA damage. We also wanted to compare 
the effects of dual knockdowns with singular knockdowns. 
Singular knockdown of SNF2LT similarly triggered DNA 
damage as did singular knockdown of SNF2L as measured 
by the Comet assay (Figure 4A). This was observed in 
all HM lines examined. H2AX is a surrogate marker of 
DNA damage. DNA damage results in an immediate 
phosphorylation of the histone H2A family member H2AX 
at Ser139. Ser139-phosphorylated H2AX localizes to sites 
of DNA damage at subnuclear foci. We examined the level 
of phosphorylated H2AX (p-H2AX) by Western blotting 
and found that p-H2AX was significantly increased with 
the singular knockdowns of either SNF2L or SNF2LT in 
all HM lines examined (Figure 4B). Dual knockdowns of 
both SNF2L and SNF2LT similarly led to DNA damage 
determined by both the Comet assay as well as by an 
increase in p-H2AX (data not shown). 
Singular v dual knockdowns of SNF2L/SNF2LT 
and opposite effects on the DNA damage response 
and the cell cycle 
DNA damage is thought to activate a DNA damage 
response, in which the center is the ATM/ATR kinase 
signaling  pathway.  ATM/ATR  kinases  phosphorylate 
the downstream effectors such as p53, Chk1, Chk2 and 
BRCA1. To this end, we investigated whether the critical 
DNA  damage  response  network  is  activated  by  DNA 
damage when the DNA damage is triggered by singular v 
dual knockdowns of SNF2L and SNF2LT. We examined 
this DNA damage response in a number of different 
HM lines including MDA-MB-468, MDA-MB-231 and 
HeLa. We used western blotting to examine the levels 
of phosphorylated proteins of ATM, ATR, BRACA1, 
Chk1 and Chk2. Neither singular nor dual knockdowns 
of SNF2L and SNF2LT resulted in an increase in 
phosphorylated ATM. Singular knockdowns of SNF2L and 
SNF2LT however resulted in increased phosphorylations 
of ATR, CHK1, CHK2 but no alterations of their 
respective total proteins (data not shown). Interestingly Oncotarget 2012; 3:  475-489 485 www.impactjournals.com/oncotarget
while the singular knockdown of SNF2L led to an increase 
in phosphorylated BRCA1 [21], the singular knockdown 
of SNF2LT did not do so. However dual knockdowns 
of both SNF2L and SNF2LT did not result in increased 
phosphorylations of ATR, BRCA1, CHK1, CHK2 (data 
not shown). Therefore dual knockdowns did not result in 
a typical DNA damage response.
Singular  v  dual  knockdowns  of  SNF2L  and 
SNF2LT had different effects on the triggering of cell 
cycle checkpoints. Singular knockdowns of SNF2L and 
SNF2LT resulted in nearly identical increases in relative 
levels of p53 mRNA (Figure 5A), 14-3-3 σ (Figure 5B) 
and GADD45A (Figure 5C). However dual knockdowns 
of SNF2L and SNF2LT resulted in no appreciable 
alterations in these critical cell cycle checkpoint proteins 
(Figure 5A; Figure 5B; Figure 5C). Singular knockdowns 
of SNF2L and SNF2LT also resulted in an increase in 
phosphorylation  of  p53  but  dual  knockdowns  did  not 
alter phosphorylation of p53 (data not shown). Since the 
cellular responses to DNA damage, such as cell cycle 
arrest, DNA repair, chromatin remodeling, and apoptosis 
are all thought to be well coordinated, we investigated 
whether  singular  v  dual  knockdowns  of  SNF2L  and 
SNF2LT led to alterations in the cell cycle. Our results 
indicated that the HM lines examined exhibited a mild 
G2/M  arrest  with  either  singular  SNF2L  or  SNF2LT 
knockdown. Dual knockdown did not result in a cell cycle 
arrest. In fact dual knockdowns resulted in an increase in 
proliferation (Figure 3C). Our results also showed that 
with singular knockdowns, the level of phosphorylated 
cdc2 was increased but not the level of phosphorylated Rb 
(Ser795) (data not shown). Since the cdc2/cyclin B kinase 
is thought to be pivotal in regulating the G2/M transition 
and Rb thought to control progression through late G1/S, 
our findings indicated that the effects of either SNF2L or 
SNF2LT inhibition on the cell cycle were largely directed 
at checkpoints that regulate G2/M, a finding confirmed by 
the mild G2/M arrest noted on flow cytometric analysis. 
Our observations regarding the critical targets of p53: 
GADD45  and  14-3-3σ  also  being  increased  in  either 
singular  SNF2L  or  SNF2LT  knockdown  but  not  dual 
knockdown again emphasize the fundamental differences 
between singular v dual knockdown with regard to effects 
on the cell cycle. Since GADD45A and 14-3-3σ both 
target the cyclin B/ cdc2 complex, this would appear as 
further confirmatory evidence that G2/M is targeted with 
either singular knockdown but not dual knockdown. 
Singular v dual knockdowns of SNF2L/ SNF2LT 
and opposite effects on apoptosis 
Staining  with  FITC-conjugated  annexin  V  and 
propidium iodide (PI) was used to identify subpopulations 
of cells with apoptosis. With singular knockdowns of 
either SNF2L and SNF2LT using MDA-MB-468 cells, a 
significant and near equivalent degree of apoptosis was 
induced (Figure 6A). Dual knockdowns did not result 
in apoptosis over levels induced by the NCSI negative 
control.  We  applied  real-time  PCR  to  detect  which 
apoptotic pathway was activated when either SNF2L or 
SNF2LT was knocked down. Although either singular 
knockdown resulted in the near equivalence in the degree 
of  apoptosis,  different  apoptotic  pathways  appeared 
involved. With SNF2L knockdown (Figure 6B), increased 
Apaf-1 and increased caspase-9 expression was observed. 
With SNF2LT knockdown, we found instead that caspase 
8, BAD and BIK increased (Figure 6B). Therefore, the 
apoptotic  pathway  triggered  by  SNF2LT  knockdown 
appeared different from the apoptotic pathway caused by 
SNF2L knockdown. Dual knockdowns did not appreciably 
activate any caspase pathway and were nearly identical to 
NCSI knockdown (Figure 6C). Schematic summarizes our 
findings (See Supplementary Information on line).
SNF2LT overexpression and apoptosis 
Based on our prior experiments we reasoned that 
since  SNF2L  knockdown  inhibited  cell  growth,  that 
SNF2L overexpression might be expected to enhance 
cell  growth. To  investigate  whether  the  expression  of 
SNF2LT  would  promote  cell  growth,  we  constructed 
an expression vector that overexpressed SNF2LT both 
constitutively and conditionally. We examined the effects 
of SNF2LT overexpression by both transient as well as 
stable transfections. Surprisingly we did not observe an 
increase in cell growth but rather an inhibition of cell 
growth  and  an  induction  of  apoptosis.  From  this  we 
reasoned that it was the ratio of SNF2LT to SNF2L that 
determined cell proliferation v apoptosis and that the 
singular overexpression of either full length SNF2L or its 
truncated isoform, SNF2LT was the ratio equivalence of 
singular knockdowns with the result being cell cycle arrest 
and cell death (See Supplementary Information on line). 
DISCUSSION
Epigenetic changes in gene expression play 
important roles in the development, progression and 
ultimate therapeutic targeting of human cancers [29-31]. 
In addition to the major mechanisms of DNA methylation 
and histone modification thought to regulate epigenetic 
changes [2,3,32,33], altered nucleosome positioning 
through chromatin-remodeling complexes are playing 
increasingly prominent roles in this area [4,5,11,12,13]. 
Loss of SNF2L complex activity could represent a novel 
mechanism for altering gene expression during tumor 
progression. Similarly other types of SNF2L complex 
alterations could prove deleterious to cancer cells. The 
SNF2L complex itself could therefore be a potential 
therapeutic target. Oncotarget 2012; 3:  475-489 486 www.impactjournals.com/oncotarget
In studying SNF2L, we discovered a novel truncated 
isoform, SNF2LT which formed the basis of the present 
study. When compared to full length SNF2L, SNF2LT 
lacked three important domains: HAND, SANT and 
SLIDE. Truncated isoforms usually have antagonistic 
effects, eg., dominant negative effects, on their full length 
molecule. Here SNF2LT seemed synergistic. However, 
we compared the effects of SNF2LT knockdown with 
the  effects  of  SNF2L  knockdown  and  although  there 
were some minor differences in the changes effected by 
SNF2L v SNFLT knockdown on select cell cycle proteins, 
eg.  p-BRCA1  and  apoptosis  pathways  triggered,  eg. 
caspase 9 v caspase 8, there was much more in common 
between singular SNF2L v singular SNF2LT knockdown 
in inducing DNA damage, a DNA damage response, cell 
cycle arrest and apoptosis selectively in cancer cell lines. 
Therefore SNF2LT’s effects on SNF2L certainly were 
not of a dominant negative nature. The effects of dual 
knockdowns of SNF2L and SNF2LT were very different 
than  their  singular  knockdowns.  Dual  knockdown 
induced DNA damage but did not result in a DNA damage 
response, a cell cycle arrest or apoptosis. In fact cancer 
cell  lines  subjected  to  dual  knockdown  paradoxically 
exhibited increased cell growth. Our findings indicated 
that SNF2L and its isoform tightly regulate the cancer 
cell’s response to DNA damage. Cancer cell lines which 
endogenously express low levels of both SNF2L and its 
isoform would mimic the situation of dual knockdown 
and would experience DNA damage allowed to propagate 
unchecked.
SNF2LT is not the only alternatively spliced isoform 
of SNF2L to have been described but it is perhaps the 
most important isoform because of its near ubiquity of 
expression, the similar functional consequences of its 
singular knockdown compared with SNF2L knockdown 
and its presumed interactions (direct or indirect) with 
the full length molecule. A number of other alternatively 
spliced variants of SNF2L expressed in multiple cell 
types and exhibiting different subcellular localizations 
and functions have been described [34,35]. These specific 
isoforms were generated through the alternate use of exons 
1 and 13, and by the use of alternate donor splice sites 
within exon 24. Alternate splicing within exon 24 removed 
a NLS sequence and altered the subcellular distribution 
of the SNF2L protein [34,35]. Still another splice variant 
of human SNF2L called SNF2L +13 which contained a 
nonconserved in-frame exon within the conserved catalytic 
core domain of SNF2L has been described [22]. This latter 
variant of SNF2L, SNF2L + 13, retained its ability to 
incorporate into multiprotein complexes but was devoid 
of enzymatic activity. This SNF2L + 13 splice variant was 
predominately found in nonneuronal cells of the nervous 
system. None of these other splice variants exhibited the 
near ubiquity of expression of SNF2LT. None of these 
other splice variants have been demonstrated to have 
effects on DNA damage, the DNA damage response and 
the cell cycle. None of these other splice variants have 
been shown to interact directly or indirectly with full 
length SNF2L. 
Both the relative as well as the absolute amounts of 
SNF2L and its isoform SNF2LT are obviously critical to 
their functions. When the relative amounts (their ratios) 
were  altered  through  knockdown  or  overexpression, 
HM lines responded by DNA damage, a DNA damage 
response, cell cycle arrest and apoptosis. When the 
absolute  amounts  were  altered  through  either  dual 
knockdown or, presumably, in the natural situation of 
endogenously low levels of expression of both SNF2L 
as well as SNF2LT, such as occurs in MARY-X and its 
derived spheroids, the response would be different: DNA 
damage but no DNA damage response, no cell cycle arrest 
and no apoptosis. In MARY-X lymphovascular emboli 
and its in vitro derived spheroids thought to be equivalent 
to each other [36], DNA damage would be allowed to 
propagate unchecked. 
The singular effects of SNF2LT and SNF2L 
knockdown on DNA damage, the DNA damage response, 
the cell cycle and apoptosis, while strikingly similar, did 
exhibit some differences. For example, while the singular 
knockdown of SNF2L led to an increase in p-BRCA1 [21], 
the singular knockdown of SNF2LT did not do so. The 
latter results suggested that the knockdown of SNF2LT 
might selectively block the DNA repair pathway involving 
p-BRCA1. This could explain why the growth of the cells 
subjected to SNF2LT knockdown were even more reduced 
than the growth of the same cells subjected to SNF2L 
knockdown. Another  example  of  differences  between 
SNF2L and SNF2LT knockdown was not in the triggering 
of apoptosis but rather in the pathway of apoptosis which 
was triggered [37-38]. With SNF2L knockdown, Apaf-
1 was activated which, in turn, activated caspase-9 and 
the rest of the caspase cascade including caspase-3. 
With SNF2LT knockdown, caspase-9 was not activated. 
Instead, caspase-8, BAD and BIK were activated. BAD is 
a proapoptotic member of the Bcl-2 family that promotes 
cell  death  by  displacing  BAX  from  binding  to  Bcl-2 
and Bcl-xL. BIK/Nbk (Bcl-2-interacting killer/natural 
born killer) is a potent pro-apoptotic protein belonging 
to a group of the Bcl-2 family. Functionally, BIK is able 
to bind to and antagonize anti-apoptotic Bcl-2 family 
members including Bcl-2 and Bcl-xL. The apoptotic 
pathway  triggered  by  SNF2LT  knockdown  therefore 
differed from that triggered by SNF2L knockdown. 
Despite  the  differences  between  SNF2LT  and 
SNF2L knockdown with respect to certain aspects of the 
DNA damage response, ie., p-BRCA1 and the differing 
pathways  of  apoptosis,  singular  SNF2LT  and  SNF2L 
knockdowns had much more in common and this common 
response involved alterations in both the levels of p53 as 
well as its degree of phosphorylation. This common p53 
response to either SNF2LT or SNF2L knockdown, in turn, 
suggests two possible mechanisms: Oncotarget 2012; 3:  475-489 487 www.impactjournals.com/oncotarget
Mechanism #1
The inhibition of expression of SNF2LT or SNF2L 
leads to functional losses of SNF2LT or SNF2L or the 
complexes containing them which then directly causes 
DNA damage, which, in turn, activates the DNA damage 
response. In this DNA damage response, p53 is activated 
through phosphorylation on Ser15 by ATM/ATR and on 
Ser20 by Chk1/Chk2. p53 plays a very important role in 
responding to DNA damage and promoting/maintaining 
checkpoint arrest [39]. For example, phosphorylated p53 
activates its key transcriptional targets, GADD45A and 
14-3-3σ [40]. GADD45A causes the dissociation of the 
Cdc2  and  cyclin  complex  and  14-3-3σ  sequesters  the 
cyclinB/Cdc2 complex in the cytoplasm. 
Mechanism #2
The inhibition of expression of SNF2LT or SNF2L 
directly activates the expression of p53. Either mechanism 
may be occurring singly or in combination with either 
SNF2LT or SNF2L knockdown.
SNF2LT is a novel alternatively spliced truncated 
isoform of human SNF2L that lacks the three C-terminal 
structural domains: HAND, SANT and SLIDE. These 
three domains are tightly connected and move as one 
unit during the remodeling process. SANT domains of 
other proteins, in particular, have been shown to bind 
histone tails and the histone H4 tail is important for ISWI-
driven nucleosome remodeling [41]. Deletion of the H4 
tail or grafting the tail onto another histone abolishes 
ISWI ATPase stimulation and nucleosome sliding [18]. 
This means that SNF2LT loses some very important 
functions: binding to and moving along DNA during the 
remodeling process and binding to histone, in which the 
binding may be important for nucleosome remodeling. 
And yet, SNF2LT knockdown is the near equivalent of 
SNF2L  knockdown.  How  can  these  observations  be 
reconciled? Obviously it is important to understand all of 
the interactions between SNF2L and its truncated isoform, 
SNF2LT in order to reconcile these observations. SNF2L 
and SNF2LT may bind each other and form a complex 
with  BPTF  and  RbAp46/RbAp48.  In  this  complex, 
SNF2LT may modulate the function of SNF2L and vice 
versa, adding an additional layer of fine-tuned specificity 
in ATP-dependent chromatin remodeling. Certainly the 
similarities in DNA damage, the DNA damage response, 
cell cycle arrest and apoptosis with either type of singular 
knockdown suggest that SNF2L does not directly interact 
with  SNF2LT  in  a  dominant  negative  manner.  But 
SNF2LT may directly interact with SNF2L in a different 
manner in forming the complex with BPTF and RbAp46/
RbAp48 mentioned above. Co-immunoprecipitation 
experiments of endogenous substrates which bind SNF2L 
and/or its isoform would further support or refute such 
direct interactions. 
The disparate effects of SNF2LT/SNF2L dual v 
singular knockdowns, on the other hand, raise the distinct 
possibility  of  a  type  of  indirect  interaction  between 
SNF2LT and SNF2L. To further support this type of 
indirect interaction, one approach would be to analyze 
expression  profiles  following  SNF2L  knockdown, 
SNF2LT knockdown and dual knockdown determining 
their degree of overlap. Experiments are presently in 
progress to determine whether the interactions of SNF2L 
with its truncated isoform, SNF2LT are direct or indirect 
or both. 
The existence of a functional splice variant of 
SNF2L, SNF2LT that acts in cohort with SNF2L suggests 
an additional level of complexity possibly related to 
their biology. There are many examples in nature where 
master orchestration of diverse biological functions such 
as immune homeostasis, innate immunity and global 
gene expression involve regulation by splice isoform 
variants.  Such  examples  include  FOXP3  and  exon  2 
deleted FOXP3Δ2 [42], the toll-like receptor (TLR) and its 
alternatively spliced variants [43] and, in this case, SNF2L 
and its truncated isoform, SNF2LT. In all these examples, 
it seems as if the greater the master orchestration, the 
greater is the level of regulatory complexity.
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